Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma

June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlighting a deepening response over time (increasing from 67 percent presented at ASH 2020).1 These data also showed 66 percent of patients were progression free and alive at 18 months (95 percent Confidence Interval [CI], range, 54.9–75.0). The latest findings to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, showed an overall survival (OS) of 81 percent (95 percent CI, range, 71.4–87.6)1 and response rates comparable across prespecified subgroups and lines of treatment (Abstract #8005).1 Data from the CARTITUDE-1 study supported the U.S. Food and Drug Administration Biologics License Application, which has recently been accepted for priority review. “The efficacy results observed in heavily pretreated patients with multiple myeloma receiving cilta-cel are remarkable,” said Saad Z. Usmani, M.D.†, Div...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

I have been told the following by my asc. Anyone else ever come across this? “27096 is not reimbursed by Medicare when performed in an ASC. G0260 replaces 27096”
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pain Medicine Source Type: forums
In this study, it was investigated whether social support directly impacts sleep quality and whether positive psychological capital mediates and gender moderates the relationship between social support and sleep quality among this group. Methods A total of 178 patients implanted with pacemakers were recruited to participate in the study from 2 tertiary hospitals in Shandong, China. Patients were assessed using the Perceived Social Support Scale, Positive PsyCap Questionnaire, and Pittsburgh Sleep Quality Index (PSQI). Multiple linear regression and the PROCESS macro were used to test the mediating and moderated medi...
Source: Journal of Cardiovascular Nursing - Category: Nursing Tags: ARTICLES: Implantable Cardiac Devices Source Type: research
Papers released by SAGE and subgroup Nervtag warned the highly evolved Omicron super mutant strain could cause a surge in cases 'similar or even larger' than previous waves.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Brazilian President Jair Bolsonaro is facing a potential investigation into comments linking COVID-19 vaccines to AIDS
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline dur...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A c...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
This study evaluated the ability of teclistamab to induce cytotoxicity and T-cell activation.About TeclistamabTeclistamab is an investigational bispecific antibody targeting both BCMA and CD3. BCMA, B-cell maturation antigen, is expressed at high levels on multiple myeloma cells.[3],[4],[5],[6],[7] Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce cytotoxicity of the targeted cells.5,6 Results from preclinical studies demonstrate that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients.6 Teclistamab is currently being evaluated in a...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very high...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutaneo...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Allergy & Immunology | Anemia | Biotechnology | Brain | Calcium | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | China Health | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | Health Management | Heart | Hematology | Hypertension | Infectious Diseases | Learning | Legislation | Leukemia | Marketing | Myeloma | Neurology | Neuroscience | Oral Cancer | Orthopaedics | Pain | Pain Management | Pharmaceuticals | Politics | Pulmonary Hypertension | Revlimid | Science | Statistics | Study | Thrombocytopenia | Universities & Medical Training | Urology & Nephrology | Vaccines | Velcade | Women